Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01931839
Registration number
NCT01931839
Ethics application status
Date submitted
26/08/2013
Date registered
29/08/2013
Date last updated
12/05/2017
Titles & IDs
Public title
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
Query!
Scientific title
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Query!
Secondary ID [1]
0
0
VX12-809-105
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Cystic fibrosis
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lumacaftor Plus Ivacaftor Combination
Treatment: Drugs - Ivacaftor
Experimental: Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h - Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
Experimental: Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h - Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
Experimental: Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h - Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
Experimental: Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h - Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
No intervention: Arm 5 Part A: Observational Cohort - Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
Experimental: Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h - Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
Experimental: Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h - Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
Treatment: Drugs: Lumacaftor Plus Ivacaftor Combination
Fixed dose combination tablet, oral use
Treatment: Drugs: Ivacaftor
Film-coated tablet, oral use
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part A Treatment Cohort: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
AE: as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug was considered treatment-emergent.
Query!
Timepoint [1]
0
0
Day 1 up to Week 105 (Study 105)
Query!
Primary outcome [2]
0
0
Part B Treatment Cohort: Number of Participants With Treatment-Emergent AEs and SAEs
Query!
Assessment method [2]
0
0
AE: as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug was considered treatment-emergent.
Query!
Timepoint [2]
0
0
Day 1 up to Week 105 (Study 105)
Query!
Secondary outcome [1]
0
0
Part A Treatment Cohort: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) At Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [1]
0
0
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Analysis was performed using baseline of the previous study VX12-809-103 (NCT01807923) and Study VX12-809-104 (NCT01807949) for Arm 1 and 3. Analysis was performed using baseline of the current study VX12-809-105 (NCT01931839) for Arm 2 and 4.
Query!
Timepoint [1]
0
0
Baseline (Study 103/104/105); Day 15, Week 8, 16, 24, 36, 48, 60 , 72 (Study 105)
Query!
Secondary outcome [2]
0
0
Part B Treatment Cohort: Absolute Change From Baseline in Percent Predicted FEV1 at Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [2]
0
0
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Analysis was performed using baseline of Cohort 4 of previous study VX09-809-102 (NCT01225211) for Arm 6 and 7.
Query!
Timepoint [2]
0
0
Baseline (Study 102), Day 15, Week 8, 16, 24, 36, 48, 60 , 72 (Study 105)
Query!
Secondary outcome [3]
0
0
Part A Treatment Cohort: Relative Change From Baseline in Percent Predicted FEV1 at Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [3]
0
0
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Analysis was performed using baseline of the previous study VX12-809-103 (NCT01807923) and Study VX12-809-104 (NCT01807949) for Arm 1 and 3. Analysis was performed using baseline of the current study VX12-809-105 (NCT01931839) for Arm 2 and 4.
Query!
Timepoint [3]
0
0
Baseline (Study 103/104/105), Day 15, Week 8, 16, 24, 36, 48, 60 , 72 (Study 105)
Query!
Secondary outcome [4]
0
0
Part B Treatment Cohort: Relative Change From Baseline in Percent Predicted FEV1 at Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [4]
0
0
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Analysis was performed using baseline of Cohort 4 of previous study VX09-809-102 (NCT01225211) for Arm 6 and 7.
Query!
Timepoint [4]
0
0
Baseline (Study 102), Day 15, Week 8, 16, 24, 36, 48, 60 , 72 (Study 105)
Query!
Secondary outcome [5]
0
0
Part A Treatment Cohort: Absolute Change From Baseline in Body Mass Index (BMI) at Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [5]
0
0
BMI = (Weight in kilogram \[kg\]) divided by (Stature in meters \[m\]) \^2. Analysis was performed using baseline of the previous study VX12-809-103 (NCT01807923) and Study VX12-809-104 (NCT01807949) for Arm 1 and 3. Analysis was performed using baseline of the current study VX12-809-105 (NCT01931839) for Arm 2 and 4.
Query!
Timepoint [5]
0
0
Baseline (Study 103/104/105), Day 15, Week 8, 16, 24, 36, 48, 60 , 72 (Study 105)
Query!
Secondary outcome [6]
0
0
Part B Treatment Cohort: Absolute Change From Baseline in BMI at Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [6]
0
0
BMI = (Weight \[in kg\]) divided by (Stature \[in meters\]) \^2. Analysis was performed using baseline of Cohort 4 of previous study VX09-809-102 (NCT01225211) for Arm 6 and 7.
Query!
Timepoint [6]
0
0
Baseline (Study 102), Day 15, Week 8, 16, 24, 36, 48, 60 , 72 (Study 105)
Query!
Secondary outcome [7]
0
0
Part A Treatment Cohort: Number of Pulmonary Exacerbations Events Per Patient-Year
Query!
Assessment method [7]
0
0
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events per patient year were reported, where patient years = total number of days on study/336. Analysis includes all events in the Cumulative Study Period for Arm 1 and 3, and all events in the Current Study period (Study 105) for Arm 2 and 4. As per planned analysis, endpoint evaluation included subjects from the parent study VX12-809-103 and VX12-809-104 as well for cumulative study period.
Query!
Timepoint [7]
0
0
Baseline (Study 103/104) up to Week 100 (Study 105) for Arm 1 and 3 (Cumulative study period); Baseline (Study 105) up to Week 100 (Study 105) for Arm 2 and 4 (current study period)
Query!
Secondary outcome [8]
0
0
Part A Treatment Cohort: Absolute Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Domain Score at Day 15, Week 8, 16, 24, 48 and 72
Query!
Assessment method [8]
0
0
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Analysis was performed using baseline of the previous study VX12-809-103 (NCT01807923) and Study VX12-809-104 (NCT01807949) for Arm 1 and 3. Analysis was performed using baseline of the current study VX12-809-105 (NCT01931839) for Arm 2 and 4.
Query!
Timepoint [8]
0
0
Baseline (Study 103/104/105), Day 15, Week 8, 16, 24, 48, 72 (Study 105)
Query!
Secondary outcome [9]
0
0
Part B Treatment Cohort: Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 15, Week 8, 16, 24, 48 and 72
Query!
Assessment method [9]
0
0
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Analysis was performed using baseline of Cohort 4 of previous study VX09-809-102 (NCT01225211) for Arm 6 and 7.
Query!
Timepoint [9]
0
0
Baseline (Study 102 Study), Day 15, Week 8, 16, 24, 48, 72 (Study 105)
Query!
Secondary outcome [10]
0
0
Part A Treatment Cohort: Absolute Change From Baseline in BMI Z-score at Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [10]
0
0
z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is with range from -infinity to +infinity; 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI-for-age z-score was calculated by using centers for disease control and prevention (CDC) growth charts for the pediatric population. Analysis was performed using baseline of the previous study VX12-809-103 (NCT01807923) and Study VX12-809-104 (NCT01807949) for Arm 1 and 3. Analysis was performed using baseline of the current study VX12-809-105 (NCT01931839) for Arm 2 and 4.
Query!
Timepoint [10]
0
0
Baseline (Study 103/104/105), Day 15, Week 8, 16, 24, 36, 48, 60, 72 (Study 105)
Query!
Secondary outcome [11]
0
0
Part A Treatment Cohort: Absolute Change From Baseline in Body Weight at Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [11]
0
0
Analysis was performed using baseline of the previous study VX12-809-103 (NCT01807923) and Study VX12-809-104 (NCT01807949) for Arm 1 and 3. Analysis was performed using baseline of the current study VX12-809-105 (NCT01931839) for Arm 2 and 4.
Query!
Timepoint [11]
0
0
Baseline (Study 103/104/105), Day 15, Week 8, 16, 24, 36, 48, 60, 72 (Study 105)
Query!
Secondary outcome [12]
0
0
Part B Treatment Cohort: Absolute Change From Baseline in Body Weight at Day 15, Week 8, 16, 24, 36, 48, 60 and 72
Query!
Assessment method [12]
0
0
Analysis was performed using baseline of Cohort 4 of previous study VX09-809-102 (NCT01225211) for Arm 6 and 7.
Query!
Timepoint [12]
0
0
Baseline (Study 102), Day 15, Week 8, 16, 24, 36, 48, 60, 72 (Study 105)
Query!
Secondary outcome [13]
0
0
Part A Treatment Cohort: Time-to-First Pulmonary Exacerbation
Query!
Assessment method [13]
0
0
Time-to-first pulmonary exacerbation was analyzed using the Kaplan-Meier estimates. Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Analysis was performed for the Cumulative Study Period for Arm 1 and 3, and for the current study period (Study 105) for Arm 2 and 4. As per planned analysis, endpoint evaluation included subjects from the parent study VX12-809-103 and VX12-809-104 as well for cumulative study period.
Query!
Timepoint [13]
0
0
Baseline (Study 103/104) up to Week 100 (Study 105) for Arm 1 and 3 (Cumulative study period); Baseline (Study 105) up to Week 100 (Study 105) for Arm 2 and 4 (current study period)
Query!
Secondary outcome [14]
0
0
Part A Treatment Cohort: Percentage of Participants With at Least 1 Pulmonary Exacerbation
Query!
Assessment method [14]
0
0
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Analysis was performed for the Cumulative Study Period for Arm 1 and 3, and for the current study period (Study 105) for Arm 2 and 4. As per planned analysis, endpoint evaluation included subjects from the parent study VX12-809-103 and VX12-809-104 as well for cumulative study period.
Query!
Timepoint [14]
0
0
Baseline (Study 103/104) up to Week 100 (Study 105) for Arm 1 and 3 (Cumulative study period); Baseline (Study 105) up to Week 100 (Study 105) for Arm 2 and 4 (current study period)
Query!
Secondary outcome [15]
0
0
Part A Treatment Cohort: Percentage of Participants With Response Based on Relative Change in Percent Predicted FEV1 From Baseline
Query!
Assessment method [15]
0
0
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). Percentage of participants with at least 5% and 10% relative change in percent predicted FEV1 from baseline were reported. Analysis was performed using baseline of the previous study VX12-809-103 (NCT01807923) and Study VX12-809-104 (NCT01807949) for Arm 1 and 3. Analysis was performed using baseline of the current study VX12-809-105 (NCT01931839) for Arm 2 and 4. As per planned analysis, endpoint evaluation included subjects from the parent study VX12-809-103 and VX12-809-104 as well for cumulative study period.
Query!
Timepoint [15]
0
0
Baseline (Study 103/104/105); Day 15, Week 8, 16, 24, 36, 48, 60, 72, 84, 96 (Study 105)
Query!
Secondary outcome [16]
0
0
Part B Treatment Cohort: Percentage of Participants With Response Based on Relative Change in Percent Predicted FEV1 From Baseline
Query!
Assessment method [16]
0
0
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). Percentage of participants with at least 5% relative change in percent predicted FEV1 from Baseline were reported. Analysis was performed using baseline of Cohort 4 of previous study VX09-809-102 (NCT01225211) for Arm 6 and 7. As per planned analysis, endpoint evaluation included subjects from the parent study VX09-809-102 as well.
Query!
Timepoint [16]
0
0
Baseline (Study 102), Day 15, Week 8, 16, 24, 36, 48, 60, 72 (Study 105)
Query!
Secondary outcome [17]
0
0
Part A Observation Cohort: Number of Participants With Serious Adverse Events (SAEs)
Query!
Assessment method [17]
0
0
AE: as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
Query!
Timepoint [17]
0
0
up to 2 years
Query!
Eligibility
Key inclusion criteria
* Signed informed consent form (ICF), and where appropriate, signed assent form.
* Participants entering the Part A Treatment Cohort: Completed 24 weeks of study drug treatment in Study 103 or Study 104 and elect to enroll in Part A treatment cohort.
* Participants entering the Part B Treatment Cohort: Completed 56 days of study drug treatment in Cohort 4 of Study 102 and elect to enroll in Part B treatment cohort.
* Participants entering the Part A Observational Cohort: Completed 24 weeks of study drug treatment in Study 103 or Study 104, but do not elect to enroll in the Part A Treatment Cohort or do not qualify to enroll in Part A treatment cohort.
* Willing to remain on a stable CF medication regimen through the end of study (Part A and Part B Treatment Cohorts only).
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant (e.g., cirrhosis with portal hypertension).
* Pregnant and nursing females. Females of childbearing potential must have a negative pregnancy test at the Day 1 Visit.
* History of drug intolerance in the prior study that would pose an additional risk to the participant in the opinion of investigator or Vertex.
* History of poor compliance with study drug and/or procedures in the previous study as deemed by the investigator.
* Participation in an investigational drug trial (including studies investigating lumacaftor and/or ivacaftor, or studies requiring blood collections with or without administration of study drug)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1164
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
- New Lambton Heights
Query!
Recruitment hospital [2]
0
0
- Westmead
Query!
Recruitment hospital [3]
0
0
- Adelaide
Query!
Recruitment hospital [4]
0
0
- Chermside
Query!
Recruitment hospital [5]
0
0
- Herston
Query!
Recruitment hospital [6]
0
0
- South Brisbane
Query!
Recruitment hospital [7]
0
0
- Nedlands
Query!
Recruitment hospital [8]
0
0
- Subiaco
Query!
Recruitment postcode(s) [1]
0
0
- New Lambton Heights
Query!
Recruitment postcode(s) [2]
0
0
- Westmead
Query!
Recruitment postcode(s) [3]
0
0
- Adelaide
Query!
Recruitment postcode(s) [4]
0
0
- Chermside
Query!
Recruitment postcode(s) [5]
0
0
- Herston
Query!
Recruitment postcode(s) [6]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [7]
0
0
- Nedlands
Query!
Recruitment postcode(s) [8]
0
0
- Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Alaska
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arizona
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Arkansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
California
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Colorado
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Connecticut
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Florida
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Georgia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Idaho
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Illinois
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Indiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Iowa
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Kansas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Kentucky
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Louisiana
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Maine
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Maryland
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Massachusetts
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Michigan
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Minnesota
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Mississippi
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Missouri
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Nebraska
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Hampshire
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New Jersey
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
New Mexico
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
New York
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
North Carolina
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Ohio
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Oklahoma
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Oregon
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Pennsylvania
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
South Carolina
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
South Dakota
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Tennessee
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Texas
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
Utah
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Vermont
Query!
Country [40]
0
0
United States of America
Query!
State/province [40]
0
0
Virginia
Query!
Country [41]
0
0
United States of America
Query!
State/province [41]
0
0
Washington
Query!
Country [42]
0
0
United States of America
Query!
State/province [42]
0
0
West Virginia
Query!
Country [43]
0
0
United States of America
Query!
State/province [43]
0
0
Wisconsin
Query!
Country [44]
0
0
Austria
Query!
State/province [44]
0
0
Innsbruck
Query!
Country [45]
0
0
Austria
Query!
State/province [45]
0
0
Wels
Query!
Country [46]
0
0
Belgium
Query!
State/province [46]
0
0
Bruxelles
Query!
Country [47]
0
0
Belgium
Query!
State/province [47]
0
0
Gent
Query!
Country [48]
0
0
Belgium
Query!
State/province [48]
0
0
Leuven
Query!
Country [49]
0
0
Belgium
Query!
State/province [49]
0
0
Liège
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Alberta
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
British Columbia
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Nova Scotia
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Ontario
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Quebec
Query!
Country [55]
0
0
Czech Republic
Query!
State/province [55]
0
0
Brno
Query!
Country [56]
0
0
Czech Republic
Query!
State/province [56]
0
0
Plzen - Bory
Query!
Country [57]
0
0
Czech Republic
Query!
State/province [57]
0
0
Praha 5
Query!
Country [58]
0
0
Denmark
Query!
State/province [58]
0
0
Copenhagen
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Bas Rhin
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Bouches-du-Rhone
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Haute Garonne
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Herault
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Nord
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Rhone
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Bordeaux
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Paris
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Pierre Benite
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Roscoff
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Bayem
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Bayern
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Berlin
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Bochum
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Erlangen
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Essen
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Frankfurt
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Giessen
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Hannover
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Jena
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Koeln
Query!
Country [80]
0
0
Germany
Query!
State/province [80]
0
0
Leipzig
Query!
Country [81]
0
0
Germany
Query!
State/province [81]
0
0
Muenchen
Query!
Country [82]
0
0
Germany
Query!
State/province [82]
0
0
Tuebingen
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Wuerzburg
Query!
Country [84]
0
0
Ireland
Query!
State/province [84]
0
0
Dublin
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Ancona
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Firenze
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Genova
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Milano
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Roma
Query!
Country [90]
0
0
Italy
Query!
State/province [90]
0
0
Verona
Query!
Country [91]
0
0
Netherlands
Query!
State/province [91]
0
0
Amsterdam
Query!
Country [92]
0
0
Netherlands
Query!
State/province [92]
0
0
Den Haag
Query!
Country [93]
0
0
Netherlands
Query!
State/province [93]
0
0
Nijmegen
Query!
Country [94]
0
0
Netherlands
Query!
State/province [94]
0
0
Rotterdam
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Barcelona
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Valencia
Query!
Country [97]
0
0
Sweden
Query!
State/province [97]
0
0
Goteborg
Query!
Country [98]
0
0
Sweden
Query!
State/province [98]
0
0
Stockholm
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Devon
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Belfast
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Birmingham
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Bristol
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Leeds
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
London
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Newcastle
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Nottingham
Query!
Country [107]
0
0
United Kingdom
Query!
State/province [107]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Vertex Pharmaceuticals Incorporated
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of long-term treatment with lumacaftor in combination with ivacaftor in people 12 years and older with Cystic Fibrosis.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01931839
Query!
Trial related presentations / publications
Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01931839
Download to PDF